Literature DB >> 27687081

Falsely elevated serum oestradiol due to exemestane therapy.

Sanja Mandic1,2, Jϋrgen Kratzsch3, Dario Mandic1,2, Zeljko Debeljak1,4, Iva Lukic1,2, Vesna Horvat1,2, Alexander Gaudl3, Vatroslav Seric1,2.   

Abstract

In this study, we present a case of falsely elevated oestradiol (E2) concentration, determined by two immunoassays, in a breast cancer patient receiving exemestane therapy. The positive bias of immunochemical measurements was revealed using liquid chromatography tandem mass spectrometry which showed undetectable E2 concentration. The discrepancy is expected to be a consequence of the structural resemblance of E2 and exemestane sharing the same steroidal backbone. Inaccurate laboratory findings in therapy monitoring, as in this case, may lead to unnecessary changes of therapy.

Entities:  

Keywords:  Immunoassay; mass spectrometry; steroid hormones

Mesh:

Substances:

Year:  2016        PMID: 27687081     DOI: 10.1177/0004563216674031

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  5 in total

Review 1.  Falsely elevated serum estradiol in woman of reproductive age led to unnecessary intervention and delayed fertility opportunity: a case report and literature review.

Authors:  Jing Zhang; Liangzhi Xu; Lin Qiao
Journal:  BMC Womens Health       Date:  2022-06-16       Impact factor: 2.742

2.  Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy.

Authors:  Polly Niravath; Raksha Bhat; Mohamed Al-Ameri; Ahmed AlRawi; Claudette Foreman; Meghana V Trivedi
Journal:  Pharmacol Res Perspect       Date:  2017-08

3.  Analytical bias of automated immunoassays for six serum steroid hormones assessed by LC-MS/MS.

Authors:  Željko Debeljak; Ivana Marković; Jasna Pavela; Iva Lukić; Dario Mandić; Sanja Mandić; Vesna Horvat; Vatroslav Šerić
Journal:  Biochem Med (Zagreb)       Date:  2020-08-05       Impact factor: 2.313

Review 4.  Hormone Immunoassay Interference: A 2021 Update.

Authors:  Khaldoun Ghazal; Severine Brabant; Dominique Prie; Marie-Liesse Piketty
Journal:  Ann Lab Med       Date:  2022-01-01       Impact factor: 3.464

5.  Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.

Authors:  Bjørn-Erik Bertelsen; Kristin Viste; Thomas Helland; Magnus Hagland; Håvard Søiland; Jürgen Geisler; Tone Hoel Lende; Per Eystein Lønning; Jørn V Sagen; Gunnar Mellgren; Bjørg Almås
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.